Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a Phase II, randomized study
Open Access
- 1 July 2013
- journal article
- research article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. 7, 611-7
Abstract
Peer reviewed article authored by (Zarogoulidis K, Ziogas E, Boutsikou E, Zarogoulidis P, Darwiche K, Kontakiotis T, Tsakiridis K, Porpodis K, Latsios D, Chatzizisi O, Karapantzos I, Li Q, Kyriazis G). Read article or submit your manuscript for publishing.Keywords
This publication has 29 references indexed in Scilit:
- Cancer statistics for African Americans, 2013CA: A Cancer Journal for Clinicians, 2013
- IFN-γ protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanismJournal of Clinical Investigation, 2002
- Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trialThe Lancet, 2000
- A phase I study of recombinant interferon gamma administered by s.c. injection three times per week in patients with solid tumoursCancer Immunology, Immunotherapy, 1987
- Alfa interferon: combinations with other antineoplastic modalities.1987
- Angiogenic FactorsScience, 1987
- Phase I study of a combination of recombinant interferon-alpha and recombinant interferon-gamma in cancer patients.Journal of Clinical Oncology, 1986
- AUGMENTATION OF CYTOTOXICITY OF CHEMOTHERAPY BY HUMAN ALPHA-INTERFERONS IN HUMAN NON-SMALL CELL LUNG-CANCER XENOGRAFTS1986
- Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assayCancer Chemotherapy and Pharmacology, 1983
- Biochemistry of Interferons and Their ActionsAnnual Review of Biochemistry, 1982